| Drug Name |
Nintedanib |
| Drug ID |
BADD_D02470 |
| Description |
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014.[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.[A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459] |
| Indications and Usage |
In the US, nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF)[L8453] and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease.[L8462] In the EU, nintedanib is indicated in combination with docetaxel for the treatment of adult patients with metastatic, locally advanced, or locally recurrent non-small cell lung cancer of adenocarcinoma histology who have already tried first-line therapy.[L8459] |
| Marketing Status |
approved |
| ATC Code |
L01EX09 |
| DrugBank ID |
DB09079
|
| KEGG ID |
D10481
|
| MeSH ID |
C530716
|
| PubChem ID |
135423438
|
| TTD Drug ID |
D09HNV
|
| NDC Product Code |
55361-0020; 66499-0061; 0597-0143; 0597-0145; 51869-0040; 55361-0021 |
| UNII |
G6HRD2P839
|
| Synonyms |
nintedanib | Nintedanib esylate | Ofev | Vargatef | BIBF 1120 | BIBF1120 | BIBF-1120 |
